1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Breast Cancer Liquid Biopsy Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Circulating Tumor Cells (CTCs)
1.2.3 Cell-Free DNA (CfDNA)
1.2.4 Extracellular Vesicles (EVs)
1.2.5 Other Circulating Biomarkers
1.3 Market by Application
1.3.1 Global Breast Cancer Liquid Biopsy Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Diagnostic Centers
1.3.4 Laboratories
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Breast Cancer Liquid Biopsy Market Perspective (2017-2028)
2.2 Breast Cancer Liquid Biopsy Growth Trends by Region
2.2.1 Breast Cancer Liquid Biopsy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Breast Cancer Liquid Biopsy Historic Market Size by Region (2017-2022)
2.2.3 Breast Cancer Liquid Biopsy Forecasted Market Size by Region (2023-2028)
2.3 Breast Cancer Liquid Biopsy Market Dynamics
2.3.1 Breast Cancer Liquid Biopsy Industry Trends
2.3.2 Breast Cancer Liquid Biopsy Market Drivers
2.3.3 Breast Cancer Liquid Biopsy Market Challenges
2.3.4 Breast Cancer Liquid Biopsy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Breast Cancer Liquid Biopsy Players by Revenue
3.1.1 Global Top Breast Cancer Liquid Biopsy Players by Revenue (2017-2022)
3.1.2 Global Breast Cancer Liquid Biopsy Revenue Market Share by Players (2017-2022)
3.2 Global Breast Cancer Liquid Biopsy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Breast Cancer Liquid Biopsy Revenue
3.4 Global Breast Cancer Liquid Biopsy Market Concentration Ratio
3.4.1 Global Breast Cancer Liquid Biopsy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Breast Cancer Liquid Biopsy Revenue in 2021
3.5 Breast Cancer Liquid Biopsy Key Players Head office and Area Served
3.6 Key Players Breast Cancer Liquid Biopsy Product Solution and Service
3.7 Date of Enter into Breast Cancer Liquid Biopsy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Breast Cancer Liquid Biopsy Breakdown Data by Type
4.1 Global Breast Cancer Liquid Biopsy Historic Market Size by Type (2017-2022)
4.2 Global Breast Cancer Liquid Biopsy Forecasted Market Size by Type (2023-2028)
5 Breast Cancer Liquid Biopsy Breakdown Data by Application
5.1 Global Breast Cancer Liquid Biopsy Historic Market Size by Application (2017-2022)
5.2 Global Breast Cancer Liquid Biopsy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Breast Cancer Liquid Biopsy Market Size (2017-2028)
6.2 North America Breast Cancer Liquid Biopsy Market Size by Country (2017-2022)
6.3 North America Breast Cancer Liquid Biopsy Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Breast Cancer Liquid Biopsy Market Size (2017-2028)
7.2 Europe Breast Cancer Liquid Biopsy Market Size by Country (2017-2022)
7.3 Europe Breast Cancer Liquid Biopsy Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Breast Cancer Liquid Biopsy Market Size (2017-2028)
8.2 Asia-Pacific Breast Cancer Liquid Biopsy Market Size by Country (2017-2022)
8.3 Asia-Pacific Breast Cancer Liquid Biopsy Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Breast Cancer Liquid Biopsy Market Size (2017-2028)
9.2 Latin America Breast Cancer Liquid Biopsy Market Size by Country (2017-2022)
9.3 Latin America Breast Cancer Liquid Biopsy Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Breast Cancer Liquid Biopsy Market Size (2017-2028)
10.2 Middle East & Africa Breast Cancer Liquid Biopsy Market Size by Country (2017-2022)
10.3 Middle East & Africa Breast Cancer Liquid Biopsy Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 QIAGEN
11.1.1 QIAGEN Company Detail
11.1.2 QIAGEN Business Overview
11.1.3 QIAGEN Breast Cancer Liquid Biopsy Introduction
11.1.4 QIAGEN Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.1.5 QIAGEN Recent Development
11.2 Roche Diagnostics
11.2.1 Roche Diagnostics Company Detail
11.2.2 Roche Diagnostics Business Overview
11.2.3 Roche Diagnostics Breast Cancer Liquid Biopsy Introduction
11.2.4 Roche Diagnostics Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.2.5 Roche Diagnostics Recent Development
11.3 Bio-Rad Laboratories
11.3.1 Bio-Rad Laboratories Company Detail
11.3.2 Bio-Rad Laboratories Business Overview
11.3.3 Bio-Rad Laboratories Breast Cancer Liquid Biopsy Introduction
11.3.4 Bio-Rad Laboratories Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.3.5 Bio-Rad Laboratories Recent Development
11.4 Myriad Genetics
11.4.1 Myriad Genetics Company Detail
11.4.2 Myriad Genetics Business Overview
11.4.3 Myriad Genetics Breast Cancer Liquid Biopsy Introduction
11.4.4 Myriad Genetics Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.4.5 Myriad Genetics Recent Development
11.5 Menarini Silicon Biosystems
11.5.1 Menarini Silicon Biosystems Company Detail
11.5.2 Menarini Silicon Biosystems Business Overview
11.5.3 Menarini Silicon Biosystems Breast Cancer Liquid Biopsy Introduction
11.5.4 Menarini Silicon Biosystems Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.5.5 Menarini Silicon Biosystems Recent Development
11.6 Genomic Health
11.6.1 Genomic Health Company Detail
11.6.2 Genomic Health Business Overview
11.6.3 Genomic Health Breast Cancer Liquid Biopsy Introduction
11.6.4 Genomic Health Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.6.5 Genomic Health Recent Development
11.7 Thermo Fisher Scientific
11.7.1 Thermo Fisher Scientific Company Detail
11.7.2 Thermo Fisher Scientific Business Overview
11.7.3 Thermo Fisher Scientific Breast Cancer Liquid Biopsy Introduction
11.7.4 Thermo Fisher Scientific Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.7.5 Thermo Fisher Scientific Recent Development
11.8 Illumina
11.8.1 Illumina Company Detail
11.8.2 Illumina Business Overview
11.8.3 Illumina Breast Cancer Liquid Biopsy Introduction
11.8.4 Illumina Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.8.5 Illumina Recent Development
11.9 Biocept
11.9.1 Biocept Company Detail
11.9.2 Biocept Business Overview
11.9.3 Biocept Breast Cancer Liquid Biopsy Introduction
11.9.4 Biocept Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.9.5 Biocept Recent Development
11.10 Trovagene
11.10.1 Trovagene Company Detail
11.10.2 Trovagene Business Overview
11.10.3 Trovagene Breast Cancer Liquid Biopsy Introduction
11.10.4 Trovagene Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.10.5 Trovagene Recent Development
11.11 Guardant Health
11.11.1 Guardant Health Company Detail
11.11.2 Guardant Health Business Overview
11.11.3 Guardant Health Breast Cancer Liquid Biopsy Introduction
11.11.4 Guardant Health Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.11.5 Guardant Health Recent Development
11.12 RainDance Technologies
11.12.1 RainDance Technologies Company Detail
11.12.2 RainDance Technologies Business Overview
11.12.3 RainDance Technologies Breast Cancer Liquid Biopsy Introduction
11.12.4 RainDance Technologies Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.12.5 RainDance Technologies Recent Development
11.13 MDx Health
11.13.1 MDx Health Company Detail
11.13.2 MDx Health Business Overview
11.13.3 MDx Health Breast Cancer Liquid Biopsy Introduction
11.13.4 MDx Health Revenue in Breast Cancer Liquid Biopsy Business (2017-2022)
11.13.5 MDx Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
